

Time Is Muscle

Translation Into Practice

Elliott M. Antman, MD, FACC

Boston, Massachusetts

In the future, advances in the care of patients with ST-segment elevation myocardial infarction (STEMI) will not come from the analysis of trials that do not reflect current practice in an effort to rationalize extending the percutaneous coronary intervention (PCI)-related delay time. We must move beyond such arguments and find ways to shorten total ischemic time. With the launching of the American College of Cardiology's D2B Alliance and the American Heart Association's Mission: Lifeline programs, the focus is now on systems improvement for reperfusion in patients with STEMI. The D2B Alliance was developed to focus on improvement in door-to-balloon times for patients with STEMI who are undergoing primary PCI. The American Heart Association Mission: Lifeline program is a broad, comprehensive national initiative to improve the quality of care and outcomes of patients with STEMI by improving health care system readiness and response to STEMI. Improvements in access to timely care for patients with STEMI will require a multifaceted approach involving patient education, improvements in the Emergency Medical Services and emergency department components of care, the establishment of networks of STEMI-referral hospitals (not PCI capable) and STEMI-receiving hospitals (PCI capable), as well as coordinated advocacy efforts to work with payers and policy makers to implement a much-needed health care system redesign. By focusing now on system efforts for improvements in timely care for STEMI, we will complete the cycle of research initiated by Reimer and Jennings 30 years ago. Time is muscle . . . we must translate that into practice. (J Am Coll Cardiol 2008;52:1216-21) © 2008 by the American College of Cardiology Foundation

Given the urgency of reperfusion of the occluded infarct artery in patients with ST-segment elevation myocardial infarction (STEMI), it is not unexpected that the most frequently discussed aspects of management are the selection and implementation of a reperfusion strategy. Despite the importance of these topics, when attempting to write guidelines for management of STEMI, clinicians should realize that the "evidence" on which to base such recommendations is derived from databases that do not completely answer all of our questions.

For example, a frequently quoted overview by Keeley et al. (1) in which they compare fibrinolytic reperfusion with catheter-based reperfusion summarizes the experience from a total of only 7,739 patients enrolled collectively in 23 randomized trials. These 23 trials have publication dates ranging from 1990 to 2002, raising questions about their contemporary relevance because of shifts in the use of other effective therapies besides the exact mode of reperfusion for STEMI.

Furthermore, the largest difference in absolute event rates between pharmacologic and catheter-based reperfusion was in recurrent infarction (something that is difficult to diag-

nose accurately in the setting of primary percutaneous coronary intervention [PCI] for STEMI); the differences in mortality and hemorrhagic stroke, although still favoring those patients undergoing primary PCI, were much more modest. Contemporary attempts by researchers to merge the 2 reperfusion strategies in the form of facilitated PCI (a preparatory pharmacologic regimen followed at varying times by PCI) have not shown this approach to be an attractive one—there is no clear reduction in mortality or reinfarction with facilitated PCI, and concerns exist about a definite increase in the risk of bleeding (2-4).

Despite the deficiencies in the evidence base, it is generally accepted that primary PCI is the preferred mode of reperfusion, provided it can be delivered in a timely fashion by an experienced operator (>75 PCI procedures/year) and team (at least 200 PCI procedures per year, including at least 36 primary PCI procedures/year) (5). The issue centers on what is meant by a "timely fashion." Because in virtually all cases there is an inherent delay in implementation of a primary PCI strategy, many analyses have been performed to provide guidance on the acceptable delays to primary PCI—the metric "door-to-balloon" (D2B) time arose and was initially proposed to be 120 min.

By 2004, several pieces of evidence had emerged that led to a shortening of the recommended D2B time to 90 min. Concern arose that long delays to primary PCI run counter to the guiding principle that "time is muscle," as shown by

From the TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.

Manuscript received June 4, 2008; revised manuscript received July 2, 2008, accepted July 11, 2008.

Reimer and Jennings nearly 30 years ago (6). Investigators understood that the amount of myocardial salvage per unit time from the moment of coronary occlusion is not linear but rather curvilinear with the maximum amount of salvage in the first few hours after the onset of infarction, with sharp reductions in the amount of salvage thereafter as each hour passes (7).

Thus, total ischemic time is of paramount importance and often is overlooked in discussions about time to reperfusion. The importance of total ischemic time holds true regardless of whether reperfusion is attempted with a fibrinolytic or by PCI (8,9). Clinical trials in Europe testing the strategy of transfer of STEMI patients from community hospitals to PCI centers (10,11) consistently showed lower mortality in the transfer patients but also showed that it was possible to implement the PCI strategy within 90 min from randomization—giving birth to the recommendations in 2004 on both sides of the Atlantic that the system goal should be to perform primary PCI within 90 min of the first medical contact (preferably the Emergency Medical Services [EMS] team in patients who call 911 [EMS-to-balloon = 90 min], but D2B should comprise 90 min in those patients whose first medical contact is the door of the hospital) (5,12).

Several authors have argued that the benefits of primary PCI compared with fibrinolytic therapy extend well beyond the 90-min window noted previously (13). Claims have been published that the benefit of primary PCI is still observed even if there is a 3-h delay compared with the time when a fibrinolytic could be administered (14). In a patient-level analysis from 22 trials (total sample size = 6,763) that largely overlaps with the Keeley et al. (1) overview noted previously in this commentary, Boersma (15) concluded that primary PCI was associated with a lower 30-day mortality compared with fibrinolytic therapy regardless of the PCI-related delay time (a hospital-level factor).

It is hard to accept the argument that PCI-related delay time does not matter at all both on a biologic basis and also on a statistical basis. A particularly concerning observation in the Boersma meta-analysis (15) is the finding of an unusual relationship between the 30-day mortality and PCI-related delay time. Although there is the expected increase in mortality with longer delays to PCI in patients allocated to PCI, a biologically implausible pattern was observed in those allocated to fibrinolysis. The 30-day mortality in the fibrinolytic group was 8.2% when the PCI-related delay compared with fibrinolysis was 0 to 35 min, decreased to 6.8% when it was >35 to 50 min, decreased further to 5.4% when it was >50 to 62 min, increased abruptly to 9.5% when it was >62 to 79 min, and then remained at 9.6% when it was >79 to 120 min. Why should the efficiency with which a hospital can implement a primary PCI strategy have any bearing on the mortality rate when patients receive a fibrinolytic (16)?

Another difficulty with the Boersma meta-analysis (15) is the under-representation of patients with a relatively short

presentation delay. Pre-hospital fibrinolysis, which helps reduce total ischemic time, is an important treatment consideration in such patients, given the much shorter time to initiation of a reperfusion strategy compared with the time delay to implement primary PCI (17,18). When pre-hospital lysis is combined with the aggressive use of rescue PCI, 1-year mortality appears comparable with that achieved with primary PCI (19,20).

Other attempts to estimate the time tradeoff between fibrinolysis and primary PCI suggest that the mortality benefit of primary PCI is lost if it is delayed by more than 60 min compared with a fibrin-specific lytic; when one adds the door-to-needle time of 30 min for a lytic, further support is found for the recommendation of a D2B time of 90 min (21,22). Indeed, as suggested by Pinto et al. (23), the situation is much more complex than can be represented by a single number. Using a large dataset from NRMI (National Registry of Myocardial Infarction), Pinto et al. (23) showed that the equipoise point between primary PCI and a fibrinolytic may be as little as 40 min in a high-risk situation with much myocardium to salvage when one factors in the time from onset of symptoms, age of the patient, and location of the infarction (e.g., early presentation after the onset of infarction in a young patient with an anterior infarction); it may extend to 179 min in other situations (late presentation in an elderly patient with a nonanterior infarction) (23). These points emphasize, as stated in the preamble to STEMI clinical practice guidelines, that the recommendations put forward by writing committees are system goals but are not meant to supersede clinician judgment in individual cases.

The latest discussion about the 90-min system goal for implementing primary PCI is in this issue of the *Journal* by Terkelsen et al. (24), who ask, “Is there any time left for primary PCI according to the 2007 Updated American College of Cardiology (ACC)/American Heart Association (AHA) STEMI Guidelines and the D2B Alliance?” (24). Their interpretation of the 2007 ACC/AHA STEMI Guidelines is that the Writing Committee advocates what amounts to a PCI-related delay of only 40 min, and they ask that consideration be given to extending the D2B time back to 120 min.

To buttress their argument, Terkelsen et al. (24) cite much of the information discussed previously in this commentary and place emphasis on the Boersma meta-analysis (15) without commenting on the problems noted in a key figure, which they reproduced. In their Figure 1, Terkelsen et al. (24) also use unrealistically short transfer times that are not representative of experience in large parts of the U.S. (5,24,25). The D2B time of 30 min proposed by Terkelsen

Abbreviations and Acronyms

ACC	= American College of Cardiology
AHA	= American Heart Association
D2B	= door-to-balloon
EMS	= Emergency Medical Services
PCI	= percutaneous coronary intervention
STEMI	= ST-segment elevation myocardial infarction

Download English Version:

<https://daneshyari.com/en/article/2949722>

Download Persian Version:

<https://daneshyari.com/article/2949722>

[Daneshyari.com](https://daneshyari.com)